AR065947A1 - Antagonistas de los receptores de la hormona liberadora de gonadodropina (gnrh) - Google Patents

Antagonistas de los receptores de la hormona liberadora de gonadodropina (gnrh)

Info

Publication number
AR065947A1
AR065947A1 ARP080101410A ARP080101410A AR065947A1 AR 065947 A1 AR065947 A1 AR 065947A1 AR P080101410 A ARP080101410 A AR P080101410A AR P080101410 A ARP080101410 A AR P080101410A AR 065947 A1 AR065947 A1 AR 065947A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
independently
heterocycle
occurrence
Prior art date
Application number
ARP080101410A
Other languages
English (en)
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of AR065947A1 publication Critical patent/AR065947A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Se describen composiciones que contienen un compuesto de esta invencion de combinacion con un portador farmacéuticamente aceptable y el uso de los mismos para preparar medicamentos. Enfermedades derivadas de la regulacion hipofisaria de losesteroides gonadales, como disfunciones sexuales en mujeres y hombres. Reivindicacion 1: Un compuesto que tiene la siguiente estructura (1) y estereoisomeros, ésteres, solvatos y sales farmacéuticamente aceptables del mismo, en el que: A espiridilo, fenilo, quinolinilo, naftiridinilo, tienopirimidinilo o 2-oxo-pirimidinilo, en el que el piridilo, fenilo, quinolinilo, tienopirimidinilo o 2-oxo-pirimidinilo está sustituido con 0-5 R4; R1a es H, halogeno, alquilo C1-4, alcoxilo C1-4 otrifluorometilo; R1b y R1c son iguales o diferentes y son independientemente H, halogeno, hidroxilo, haloalquilo C1-4, -alquil C1-6-(R5)p, O-alquil C1-6-(R5)p, -alquil C1-6-O-alquil C1-6-(R5)p, -NR7-alquil C1-6-(R5)p o -S(O)m-alquil C1-6-(R5)p; R1des F, Cl, metilo, CF3 o ciano; R2 es alquil C1-4-(R5)p; R2a es fenilo sustituido con 0-4 R3, heteroarilo sustituido con 0-4 R3, alquilo C1-6 sustituido con 0-4 R3, arilalquilo C1-4 sustituido con 0-4 R3o heteroarilalquilo C1-4 sustituido con 0-4 R3;o R2 y r2a tomados junto con el nitrogeno al que están unidos forman un heterociclo que está sustituido con 0-4 R3; R3 en cada aparicion es independientemente halogeno, ciano, haloalquilo C1-4, R5, -alquil C1-6-(R5)p, -alquil C1-6-O-alquil C1-6-(R5)p, -O-alquil C1-6-(R5)p, -NR7-alquil C1-6-(R5)p, -S(O)m-alquil C1-6-(R5)p, -O-alquil C1-6NR7-alquil C1-6-(R5)p, heterociclo-(R5)p; R4 en cada aparicion es independientemente halogeno, alquilo C1-6, haloalquilo C1-4, alcoxilo C1-6, hidroxilo,ciano, tioalquilo C1-6, -C(O)NR7R8 o heteroarilo de 5 miembros; R5 en cada aparicion es independientemente H, hidroxilo, -OC(O)-alquilo C1-6, -OC(O)O-alquilo C1-6, -OC(O)-alquil C1-6-NR7R8, -COOR6, -C(O)NR7R8, -NR7C(O)NR7R8, -S(O)2NR9R9, -S(O)m-alquilo C1-4, -NR7R8, alcoxilo C1-6, -O-heterociclo, o heterociclo en el que dicho heterociclo y dicho -O-heterociclo están sustituidos con 0-4 grupos seleccionados de halogeno, alquilo C1-6, haloalquilo C1-4, hidroxilo, oxo, tio, -NH2, -S(O)2alquilo C1-4 y -COOH; R6 en cada aparicion es independientemente H, alquilo C1-4, alquil C1-4-O-C(O)-alquilo C1-6 o alquil C1-4-O-C(O)-O-alquilo C1-6; R7 en cada aparicion es independientemente H, alquilo C1-4, hidroxilo o heterociclo en el quedicho heterociclo está sustituido con 0-4 frupos seleccionados de halogeno, alquilo c1-6, hidroxilo, ceto, -NH2 y -COOH; R8 en cada aparicion es independientemente H, alquilo C1-4, haloalquilo C1-4, -C(O)-alquilo C1-4, -C(O)-haloalquilo C1-4, -S(O)m-haloalquilo C1-4 o -S(O)m-alquilo C1-4; R9 en cada aparicion es independientemente H, alquilo C1-4 o C(O)alquilo C1-4; m es 0-2; y p en cada aparicion es independientemente 1-3.
ARP080101410A 2007-04-06 2008-04-04 Antagonistas de los receptores de la hormona liberadora de gonadodropina (gnrh) AR065947A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91061907P 2007-04-06 2007-04-06

Publications (1)

Publication Number Publication Date
AR065947A1 true AR065947A1 (es) 2009-07-15

Family

ID=39731245

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101410A AR065947A1 (es) 2007-04-06 2008-04-04 Antagonistas de los receptores de la hormona liberadora de gonadodropina (gnrh)

Country Status (8)

Country Link
US (2) US8263588B2 (es)
AR (1) AR065947A1 (es)
CL (1) CL2008000986A1 (es)
PA (1) PA8775701A1 (es)
PE (1) PE20090236A1 (es)
TW (1) TW200845974A (es)
UY (1) UY31008A1 (es)
WO (1) WO2008124614A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR065948A1 (es) 2007-04-06 2009-07-15 Neurocrine Biosciences Inc Antagonistas del receptor de la hormona liberadora de gonadotropina y procedimientos relacionados con los mismos
AU2012284184B2 (en) 2011-07-18 2017-03-09 Merck Patent Gmbh Benzamides

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826833A (en) * 1984-01-30 1989-05-02 Pfizer Inc. 6-(Substituted)methylene-penicillanic and 6-(substituted)hydroxymethylpenicillanic acids and derivatives thereof
JPH03173865A (ja) 1988-11-11 1991-07-29 Banyu Pharmaceut Co Ltd 置換アリルアミン誘導体、その製造法及びその用途
US5082849A (en) * 1989-07-13 1992-01-21 Huang Fu Chich Quinolinyl-benzopyran derivatives as antagonists of leukotriene D4
ATE128128T1 (de) 1990-06-29 1995-10-15 Upjohn Co Antiatherosclerotische und antithrombotische 2- amino-6-phenyl-4h-pyran-4-one.
GB9125515D0 (en) * 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
KR0126300B1 (ko) * 1992-12-28 1997-12-26 나이토 하루오 레티노이드 수용체(rar)에 결합하는 헤테로고리 탄산유도체
DE4323916A1 (de) 1993-07-16 1995-01-19 Basf Ag Substituierte 2-Phenylpyridine
HUT77034A (hu) 1994-09-02 1998-03-02 Novartis Ag. Ribonukleinsavak hasítására szolgáló oligonukleotid konjugátumok, készítmények és eljárás
DE4439332A1 (de) 1994-11-04 1996-05-09 Bayer Ag Substituierte Azolylsulfonylphenyluracile
CA2276278C (en) * 1997-02-27 2009-04-07 Takeda Chemical Industries, Ltd. Amine compounds, their production and use
GB9707830D0 (en) 1997-04-18 1997-06-04 Smithkline Beecham Plc Novel compounds
TR200000073T2 (tr) 1997-07-11 2000-06-21 Smithkline Beecham P.L.C. 5-HT6 Reseptör antagonistleri olan sülfonamid türevleri ve bunların hazırlanma prosesi
US6258822B1 (en) * 1997-08-06 2001-07-10 Abbott Laboratories Urokinase inhibitors
AU3665199A (en) 1998-04-29 1999-11-16 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
FR2779963A1 (fr) * 1998-06-22 1999-12-24 Centre Nat Rech Scient Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
ATE272633T1 (de) * 1998-12-23 2004-08-15 Lilly Co Eli Aromatische amiden
AU767440B2 (en) 1999-05-14 2003-11-13 Neurocrine Biosciences, Inc. Imidazo- and pyrrolo(1,2-A)pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists
MXPA02003614A (es) 1999-10-15 2002-10-23 Neurocrine Biosciences Inc Antagonistas del receptor de la hormona liberadora de ganadotropina y metodos relacionados con los mismos..
PT1255738E (pt) 2000-01-25 2012-06-19 Neurocrine Biosciences Inc Antagonistas do receptor da hormona de libertação da gonadotrofina e métodos relacionados com os mesmos
DE60141871D1 (de) * 2000-05-05 2010-06-02 Wallac Oy Oligonukleotidmarkierungsstoffe und ihre Verwendung
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
AU2001276645A1 (en) 2000-10-18 2002-04-29 Pfizer Products Inc. Combination of statins and sorbitol dehydrogenase inhibitors
MXPA03009130A (es) 2000-10-20 2004-02-26 Biocryst Pharm Inc Compuestos de biarilo que funcionan como inhibidores de proteasa serina.
DE10059418A1 (de) * 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
PT1383731E (pt) * 2001-04-06 2009-11-03 Biocryst Pharm Inc Compostos de biarilo como inibidores de serina-protease
JP2002338537A (ja) 2001-05-16 2002-11-27 Mitsubishi Pharma Corp アミド化合物およびその医薬用途
US6740656B2 (en) 2001-08-02 2004-05-25 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US6939883B2 (en) 2001-08-02 2005-09-06 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
JP2005504034A (ja) 2001-08-02 2005-02-10 ニューロクライン バイオサイエンシーズ， インコーポレイテッド ゴナドトロピン放出性ホルモンレセプターアンタゴニストとしてのピリジノン誘導体およびピリダジノン誘導体
AU2002324586B2 (en) 2001-08-02 2008-04-24 Neurocrine Biosciences, Inc. 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists
GB0215650D0 (en) * 2002-07-05 2002-08-14 Cyclacel Ltd Bisarylsufonamide compounds
AU2003251944B2 (en) 2002-07-15 2008-06-26 Myriad Genetics, Inc. Compounds, compositions, and methods employing same
ATE454378T1 (de) 2002-11-01 2010-01-15 Vertex Pharma Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
WO2004052371A2 (en) 2002-12-11 2004-06-24 7Tm Pharma A/S Cyclic quinoline compounds for use in mch receptor related disorders
AR043633A1 (es) * 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
EP1611123B8 (en) 2003-04-09 2013-11-13 Exelixis, Inc. Tie-2 modulators and methods of use
US7429603B2 (en) 2003-04-25 2008-09-30 3-Dimensional Pharmaceuticals, Inc. C-fms kinase inhibitors
JP4658044B2 (ja) 2003-07-07 2011-03-23 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 性腺刺激ホルモン放出ホルモンレセプターアンタゴニストとしてのピリミジン−２，４−ジオン誘導体
NZ544747A (en) 2003-07-07 2009-06-26 Neurocrine Biosciences Inc Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
ES2387495T3 (es) 2003-07-07 2012-09-25 Neurocrine Biosciences, Inc. Arilpirimidinas útiles en el tratamiento de trastornos relacionados con las hormonas sexuales, tales como endometriosis, cáncer de próstata y similares
MXPA06000915A (es) 2003-07-25 2006-03-30 Novartis Ag Inhibidores de quinasa p-38.
WO2005019188A1 (ja) 2003-08-22 2005-03-03 Takeda Pharmaceutical Company Limited 縮合ピリミジン誘導体およびその用途
WO2005020921A2 (en) 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
US7504401B2 (en) * 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
AR046698A1 (es) 2003-11-11 2005-12-21 Ishihara Sangyo Kaisha Derivado bifenilo o su sal, y pesticida que lo contienen como un ingrediente activo
AU2004297250A1 (en) * 2003-12-05 2005-06-23 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxylic acid amide compounds as IKK inhibitors
WO2005067502A2 (en) * 2004-01-02 2005-07-28 Merck & Co., Inc. Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity
GB0402137D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
US7585859B2 (en) 2004-05-06 2009-09-08 Plexxikon, Inc. PDE4B inhibitors and uses therefor
US7683097B2 (en) 2004-05-27 2010-03-23 Propharmacon Inc. Topoisomerase inhibitors
WO2006000358A1 (de) 2004-06-25 2006-01-05 Basf Aktiengesellschaft 2, 4, 5, 6-substituierte pyridine, verfahren zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen
EP1789381A4 (en) 2004-07-12 2009-11-11 Merck & Co Inc Histone deacetylase INHIBITORS
KR20150090263A (ko) 2004-09-02 2015-08-05 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
CN101080396A (zh) 2004-10-15 2007-11-28 阿斯利康(瑞典)有限公司 作为B－Raf抑制剂的喹喔啉
JP2008516989A (ja) 2004-10-19 2008-05-22 コンパス ファーマシューティカルズ リミティド ライアビリティ カンパニー 組成物及び抗腫瘍剤としてのその使用
WO2006083005A1 (ja) * 2005-02-03 2006-08-10 Takeda Pharmaceutical Company Limited 縮合ピリミジン誘導体およびその用途
CA2599992A1 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Acridine and quinoline dervatives as sirtuin modulators
WO2006133559A1 (en) 2005-06-14 2006-12-21 Merck Frosst Canada Ltd. Reversible inhibitors of monoamine oxidase a and b
NZ567300A (en) * 2005-10-19 2010-11-26 Kissei Pharmaceutical Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof
AR065948A1 (es) * 2007-04-06 2009-07-15 Neurocrine Biosciences Inc Antagonistas del receptor de la hormona liberadora de gonadotropina y procedimientos relacionados con los mismos

Also Published As

Publication number Publication date
WO2008124614A1 (en) 2008-10-16
US8507536B2 (en) 2013-08-13
PA8775701A1 (es) 2009-04-23
US20130040975A1 (en) 2013-02-14
US8263588B2 (en) 2012-09-11
US20100184741A1 (en) 2010-07-22
UY31008A1 (es) 2008-11-28
PE20090236A1 (es) 2009-03-13
CL2008000986A1 (es) 2008-10-17
TW200845974A (en) 2008-12-01

Similar Documents

Publication Publication Date Title
AR065948A1 (es) Antagonistas del receptor de la hormona liberadora de gonadotropina y procedimientos relacionados con los mismos
CO6231025A2 (es) Sal de napadisilato de 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2
PE20181093A1 (es) Compuestos heterociclicos y usos de los mismos
AR069494A1 (es) Derivados de acidos fosfonicos
AR051461A1 (es) Compuesto de pirazolo[1,5-a]pirimidin-7-il-amina forma poliformica 1 de [3-(4-metoxi-2-metil-fenil)-2,5-dimetil-pirazolo[1,5-a]pirimidin-7-il]-[(s)-1-(3-metil-[1,2,4]oxadiazol-5-il)-propil]-amina, composicion farmaceutica que lo comprende y su uso para prepararla
AR077977A1 (es) Compuestos y composiciones como inhibidores de cinasa de proteina
PE20160173A1 (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD ANTAGONISTA DE RECEPTORES MUSCARINICOS ASI COMO ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENERGICO
AR038834A1 (es) Derivados de nicotinamida utiles como inhibidores de pde4; composiciones farmaceuticas que los contienen; proceso de preparacion del compuesto y uso del mismo para fabricar un farmaco
AR078536A1 (es) Derivados de pirazol como ligandos del receptor de estrogeno
AR074024A1 (es) Compuesto de arilazol-2-il-cianoetilamino enantiomericamente enriquecidos, composicion plaguicida y su uso para prevenir la infeccion parasitaria
AR065622A1 (es) Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona
AR062074A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa
AR035371A1 (es) Aminotiazoles, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento
AR097024A1 (es) Derivados sustituidos de quinazolin-4-ona
UY28861A1 (es) Nuevas combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias
RU2009113612A (ru) Ацетамидные производные хиназолинона и изохинолинона
AR075597A1 (es) Derivados de indol como antagonistas de receptores crth2, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del asma y otras enfermedades alergicas .
AR048495A1 (es) Benzoil amino heterociclicos, utiles para el tratamiento de enfermadades intermediadas por glk
CR8649A (es) Derivados de formamidina para el tratamiento de enfermedades
AR078045A1 (es) Derivados de pirimidina, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer
AR094840A1 (es) Pirazoles fungicidas
AR106100A1 (es) Compuestos bicíclicos como inhibidores duales atx / ca
WO2009043320A3 (en) Substituted 6-(alkylbenzylamino)purine derivatives for use as cytokinin receptor antagonists and preparations containing these derivatives
AR055431A1 (es) Derivados del acido 4-amino-tieno[3,2-c]piridina-7-carboxilico
AR087607A1 (es) Derivados de piridazinona

Legal Events

Date Code Title Description
FB Suspension of granting procedure